<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01335230</url>
  </required_header>
  <id_info>
    <org_study_id>UC 10110905</org_study_id>
    <nct_id>NCT01335230</nct_id>
  </id_info>
  <brief_title>The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected Patients</brief_title>
  <official_title>Exploring the Role of Gut-associated TH17 in Microbial Translocation in HIV and HCV/HIV Co-infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to explore what role immune cells within the gut (the
      sigmoid colon) have locally and on the immune system of patients infected with HCV, HIV or
      HCV/ HIV co-infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective 1: Characterization of the Gut Associated Lymphocytes (GALT) in HIV, HCV and
      coinfected patients regarding the role of Th17 and cytokine profiles.

      Hypothesis 1a: HIV and HCV/HIV coinfection is associated with changes in Th17 numbers and
      functions in GALT.

      Hypothesis 1b: HIV and HCV/HIV coinfection is associated with changes in cytokine profiles in
      intestinal mucosa.

      Objective 2: Identify the relationship between changes in Gut Associated Lymphocytes (GALT)
      in HIV, HCV and coinfected patients and markers of microbial translocation.

      Hypothesis 2a: Changes in GALT are associated with increase in microbial translocation in
      HIV, HCV and coinfected patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Exploring the Role of Gut-associated Th17 in Microbial Translocation in HIV and HCV/HIV Coinfected Patients.</measure>
    <time_frame>One year</time_frame>
    <description>We measure gene transcription of the colon tissues (relative expression fold changes of gene transcription compared to control). No preselected criteria were used to assess the participants. Data were analyzed and compared among each group. Relative expression levels of LEAP-2 (Liver expressed anti-microbial peptide-2) in the four groups were shown in the table below. Detailed of other genes had been published in Shata MT, et al, J. Clin Pathology 2013, Nov 66(11):967-75. PMID 23940131, and Abdel-Hameed et al, J. Acquir Immune Defic Syndr. 2013 Jul 10 PMID: 23846566</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>HIV</condition>
  <condition>Hepatitis C, Chronic</condition>
  <condition>HCV Coinfection</condition>
  <arm_group>
    <arm_group_label>10 HIV mono-infected subjects</arm_group_label>
    <description>10 subjects infected with HIV only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 HCV mono-infected subjects</arm_group_label>
    <description>10 subjects infected with HCV only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 HIV/HCV co-infected subjects</arm_group_label>
    <description>10 subjects infected with both HIV and HCV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 control subjects</arm_group_label>
    <description>10 subjects without HIV, HCV, or both</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Colon tissues
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The investigators plan to enroll 40 human subjects including 10 HIV mono-infected, 10 HCV
        mono-infected, 10 HIV/HCV co-infected patients, and 10 control subjects from the outpatient
        clinic at the University of Cincinnati College of Medicine.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  are at least age 18, but not older than 70 years old

          -  have HIV, HCV or both

          -  do not have HIV, HCV or both, and are having a screening colonoscopy or flexible
             sigmoidoscopy for abdominal pain or colon cancer screening (control subject)

        Exclusion Criteria:

          -  have a history of inflammatory bowel diseases (IBD) or suspected IBD

          -  have a history of autoimmune diseases including rheumatoid arthritis

          -  are taking systemic immunomodulators

          -  are pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Tarek Shata, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Shata MT, Abdel-Hameed EA, Hetta HF, Sherman KE. Immune activation in HIV/HCV-infected patients is associated with low-level expression of liver expressed antimicrobial peptide-2 (LEAP-2). J Clin Pathol. 2013 Nov;66(11):967-75. doi: 10.1136/jclinpath-2013-201581. Epub 2013 Aug 12.</citation>
    <PMID>23940131</PMID>
  </results_reference>
  <results_reference>
    <citation>Abdel-Hameed EA, Ji H, Sherman KE, Shata MT. Epigenetic modification of FOXP3 in patients with chronic HIV infection. J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):19-26. doi: 10.1097/QAI.0b013e3182a1bca4.</citation>
    <PMID>23846566</PMID>
  </results_reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2011</study_first_submitted>
  <study_first_submitted_qc>April 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2011</study_first_posted>
  <results_first_submitted>June 24, 2013</results_first_submitted>
  <results_first_submitted_qc>July 8, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 5, 2014</results_first_posted>
  <last_update_submitted>August 27, 2015</last_update_submitted>
  <last_update_submitted_qc>August 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Mohamed Tarek Shata</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>HCV</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>HIV and Hepatitis C coinfection</keyword>
  <keyword>HIV/HCV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Coinfection</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We enrolled all the planned subjects (40) as suggested in our proposal within 15 months from University of Cincinnati outpatient clinic</recruitment_details>
      <pre_assignment_details>We excluded patients with a history of inflammatory bowel diseases (IBD) or suspected IBD, autoimmune diseases including rheumatoid arthritis, and any patients on systemic immunomodulators. Pregnant women were also excluded from the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>10 HIV Mono-infected Subjects</title>
          <description>10 subjects infected with HIV only</description>
        </group>
        <group group_id="P2">
          <title>10 HCV Mono-infected Subjects</title>
          <description>10 subjects infected with HCV only</description>
        </group>
        <group group_id="P3">
          <title>10 HIV/HCV Co-infected Subjects</title>
          <description>10 subjects infected with both HIV and HCV</description>
        </group>
        <group group_id="P4">
          <title>10 Control Subjects</title>
          <description>10 subjects without HIV, HCV, or both</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10">subjects</participants>
                <participants group_id="P2" count="10">subjects</participants>
                <participants group_id="P3" count="10">subjects</participants>
                <participants group_id="P4" count="10">subjects</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10">subjects</participants>
                <participants group_id="P2" count="10">subjects</participants>
                <participants group_id="P3" count="10">subjects</participants>
                <participants group_id="P4" count="10">subjects</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>10 HIV Mono-infected Subjects</title>
          <description>10 subjects infected with HIV only</description>
        </group>
        <group group_id="B2">
          <title>10 HCV Mono-infected Subjects</title>
          <description>10 subjects infected with HCV only</description>
        </group>
        <group group_id="B3">
          <title>10 HIV/HCV Co-infected Subjects</title>
          <description>10 subjects infected with both HIV and HCV</description>
        </group>
        <group group_id="B4">
          <title>10 Control Subjects</title>
          <description>10 subjects without HIV, HCV, or both</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.5" spread="10.7"/>
                    <measurement group_id="B2" value="56.8" spread="6.5"/>
                    <measurement group_id="B3" value="49.1" spread="6.2"/>
                    <measurement group_id="B4" value="56" spread="6.8"/>
                    <measurement group_id="B5" value="51.4" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Exploring the Role of Gut-associated Th17 in Microbial Translocation in HIV and HCV/HIV Coinfected Patients.</title>
        <description>We measure gene transcription of the colon tissues (relative expression fold changes of gene transcription compared to control). No preselected criteria were used to assess the participants. Data were analyzed and compared among each group. Relative expression levels of LEAP-2 (Liver expressed anti-microbial peptide-2) in the four groups were shown in the table below. Detailed of other genes had been published in Shata MT, et al, J. Clin Pathology 2013, Nov 66(11):967-75. PMID 23940131, and Abdel-Hameed et al, J. Acquir Immune Defic Syndr. 2013 Jul 10 PMID: 23846566</description>
        <time_frame>One year</time_frame>
        <population>All the samples were analyzed for gene array transcriptions and cytokines profiles</population>
        <group_list>
          <group group_id="O1">
            <title>10 HIV Mono-infected Subjects</title>
            <description>10 subjects infected with HIV only</description>
          </group>
          <group group_id="O2">
            <title>10 HCV Mono-infected Subjects</title>
            <description>10 subjects infected with HCV only</description>
          </group>
          <group group_id="O3">
            <title>10 HIV/HCV Co-infected Subjects</title>
            <description>10 subjects infected with both HIV and HCV</description>
          </group>
          <group group_id="O4">
            <title>10 Control Subjects</title>
            <description>10 subjects without HIV, HCV, or both</description>
          </group>
        </group_list>
        <measure>
          <title>Exploring the Role of Gut-associated Th17 in Microbial Translocation in HIV and HCV/HIV Coinfected Patients.</title>
          <description>We measure gene transcription of the colon tissues (relative expression fold changes of gene transcription compared to control). No preselected criteria were used to assess the participants. Data were analyzed and compared among each group. Relative expression levels of LEAP-2 (Liver expressed anti-microbial peptide-2) in the four groups were shown in the table below. Detailed of other genes had been published in Shata MT, et al, J. Clin Pathology 2013, Nov 66(11):967-75. PMID 23940131, and Abdel-Hameed et al, J. Acquir Immune Defic Syndr. 2013 Jul 10 PMID: 23846566</description>
          <population>All the samples were analyzed for gene array transcriptions and cytokines profiles</population>
          <units>relative expression levels</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="0.4"/>
                    <measurement group_id="O2" value="5.84" spread="0.5"/>
                    <measurement group_id="O3" value="5.84" spread="0.5"/>
                    <measurement group_id="O4" value="6.9" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>10 HIV Mono-infected Subjects</title>
          <description>10 subjects infected with HIV only</description>
        </group>
        <group group_id="E2">
          <title>10 HCV Mono-infected Subjects</title>
          <description>10 subjects infected with HCV only</description>
        </group>
        <group group_id="E3">
          <title>10 HIV/HCV Co-infected Subjects</title>
          <description>10 subjects infected with both HIV and HCV</description>
        </group>
        <group group_id="E4">
          <title>10 Control Subjects</title>
          <description>10 subjects without HIV, HCV, or both</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>small number of subjects enrolled in the study (10 subjects in each group). It is cross-sectional study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mohamed Tarek M. shata</name_or_title>
      <organization>University of Cincinnati, Associate Prof., PI.</organization>
      <phone>(513) 558-6110</phone>
      <email>mohamed.shata@uc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

